OakChart

enGene Therapeutics Inc

ENGNHealthcare·Biotechnology·Canada·Micro·NASD·Nov 11 • 3:59 PM ET

1.80+0.13 (7.78%)
2026-11-12 04:31 CET
Market cap
120.63 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-130.36 USD m
Free cash flow, TTM
-104.00 USD m
EPS diluted, TTM
-2.08
P/E
-
Compare

Price

ENGN against its 20, 50 and 200-day averages
2050200beatmiss
2.004.006.008.7M17.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ENGNclose 1.8020-day 1.6350-day 1.77200-day 4.021.8052w low

85.3% under the 52-week high of 12.25 on 23 Jan 2026. 52-week low 1.40 on 12 May 2026. Last 15 sessions, 24.8% high to low

Volume 3.41× normal · the line is the 50-bar volume average

Profile

ENGN
52-week range, 4% of the way up
1.4012.25

enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

Employees82
IPOFeb 01, 2022
Beta-0.25
ATR, 14d0.11
Rel volume3.41
Short float5.71%
Insider own57.56%
Inst own41.92%

Snapshot

6 groups

Valuation

Index-
Market Cap120.63M
Enterprise Value-112.50M
Income-130.36M
Sales0.00M
Book/sh3.44
Cash/sh3.98
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees82
IPOFeb 01, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.52
P/C0.45
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio10.21
Current Ratio10.21
Debt/Eq0.14
LT Debt/Eq0.13
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.08
EPS next Y-1.50
EPS next Q-0.46
EPS this Y20.83%
EPS next Y17.38%
EPS next 5Y23.88%
EPS past 3/5Y- -255.92%
Sales past 3/5Y- -
EPS Y/Y TTM-9.75%
Sales Y/Y TTM-
EPS Q/Q17.85%
Sales Q/Q-
EarningsSep 08 BMO
EPS/Sales Surpr.-10.17% -

Ownership

Insider Own57.56%
Insider Trans0.01%
Inst Own41.92%
Inst Trans-21.74%
ROA-48.84%
ROE-60.50%
ROIC-49.92%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2010.33%
SMA501.64%
SMA200-55.27%
Trades-

Technical

Shs Outstand67.01M
Shs Float28.44M
Short Float5.71%
Short Ratio2.00
Short Interest1.62M
52W High12.25 -85.31%
52W Low1.40 28.57%
Volatility7.46% 6.79%
ATR (14)0.11
RSI (14)56.61
Beta-0.25
Rel Volume3.41
Avg Volume810.71K
Volume2,765,799

Performance

Perf Week4.65%
Perf Month10.43%
Perf Quarter6.51%
Perf Half Y16.88%
Perf YTD-80.07%
Perf Year-79.59%
Perf 3Y-78.57%
Perf 5Y-
Perf 10Y-
Recom2.30
Target Price3.50
Prev Close1.67
Price1.80
Change %7.78%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 18, 2026DowngradeMMorgan StanleyEqual-Weight → Underweight
May 08, 2026DowngradeWWells FargoOverweight → Equal Weight$2+11.1%
May 08, 2026DowngradeRRaymond JamesStrong Buy → Outperform$4+122.2%
May 08, 2026DowngradePPiper SandlerOverweight → Neutral$4+122.2%
May 08, 2026DowngradeOOppenheimerOutperform → Perform
May 08, 2026DowngradeMMorgan StanleyOverweight → Equal-Weight
May 08, 2026DowngradeLLeerink PartnersOutperform → Market Perform$2+11.1%
May 08, 2026DowngradeGGuggenheimBuy → Neutral
May 08, 2026DowngradeCCitizensMkt Outperform → Mkt Perform
Apr 13, 2026InitiatedWWBB SecuritiesBuy$21.50+1,094.4%

Peers

Mkt cap
TickerCompanyMkt cap
CGONCg Oncology Inc6.49B
TARAProtara Therapeutics Inc161.32M
IBRXImmunityBio Inc7.10B
URGNUroGen Pharma Ltd1.28B
AURAAura Biosciences Inc792.01M
GNLXGenelux Corp85.06M
INOInovio Pharmaceuticals Inc152.51M
REPLReplimune Group Inc2.06B
JNJJohnson & Johnson675.03B
CTMXCytomX Therapeutics Inc464.35M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Grossman WilliamInterim Chief Medical OfficerSep 22 '26Buy1.975,10210,0515,102Sep 24 04:40 PM

News

latest 14 of 85

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-09-08-0.470-0.427-0.4690.000.009
2026Q22026-06-15-0.430-0.466-0.4340.000.0012
2026Q12026-03-09-0.440-0.560-0.4420.000.0010
2025Q42025-12-22-0.730-0.567-0.7380.000.009
2025Q32025-09-11-0.570-0.498-0.5670.000.0010
2025Q22025-06-12-0.510-0.497-0.5060.000.0010
2025Q12025-03-10-0.480-0.368-0.4830.000.009
2024Q42024-12-19-0.362-0.396-0.3390.000.007
2024Q32024-09-10-0.320-0.375-0.3200.000.006
2024Q22024-06-14-0.380-0.261-0.3800.000.005
2024Q12024-03-11-0.460-0.415-0.4620.000.002
2026Q4---0.463--0.009
2027Q1---0.338--0.004
2027Q2---0.320--0.004
2027Q3---0.313--0.004
2027Q4---0.298--0.904

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-147.24--151.220.00-
2024FY-1.460-1.460-1.4600.000.00
2025FY-2.290-2.102-2.2910.000.00
2026FY--1.813--0.00
2027FY--1.498--5.83
2028FY--1.010--39.31
2029FY--0.470--99.10
2030FY--0.222--175.81

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-147000.000.000.00
2026Q4S2026-09-146000.000.000.00
2026Q4S2026-09-085000.000.000.00
2026Q4S2026-08-155000.000.000.00
2026Q4S2026-06-196000.000.000.00
2026Q4S2026-06-157000.000.000.00
2026Q4S2026-03-107000.000.000.00
2026Q4S2026-03-095000.000.000.00
2026Q4S2025-12-235000.000.000.00
2026Q4S2025-11-114000.000.000.00
2026Q4S2025-11-104000.000.000.00
2026Q4S2025-11-094000.000.000.00
2026Q4S2025-11-084000.000.000.00
2026Q4S2025-11-074000.000.000.00

Estimate history

EPS, annual-0.0140.002-151.224-1.46-2.295-2.0802
Period20212022202320242025TTM
EPS, quarterly-0.32-0.339-0.483-0.506-0.567-0.738-0.442-0.434-0.466
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual15.81315.81323.19850.97752.01967.014
Period20212022202320242025MRQ
Shares, quarterly44.21650.97750.97851.07151.10652.01966.98966.98967.014
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.720.510.320.170.000.00
Gross Profit-0.72-0.51-0.32-0.170.000.00
Selling, General and Administrative Excl. Other135.93122.6661.9725.891.83-
Research and Development96.2694.4838.3116.46--
Other Operating Expense0.000.000.000.000.000.00
Operating Income-136.65-123.17-62.30-26.06-1.83-0.23
Interest Expense3.072.992.804.950.000.00
Unusual Expense0.490.000.3769.880.000.00
Net Income Before Taxes-130.86-117.30-55.16-99.900.03-0.23
Income Taxes-0.500.00-0.020.020.000.00
Consolidated Net Income-130.36-117.30-55.14-99.920.03-0.23
Net Income From Continuing Operations-130.36-117.30-55.14-99.920.03-0.23
Net Income-130.36-117.30-55.14-104.740.03-0.23
EPS (Recurring)-1.86-2.29-1.45-80.600.00-0.01
EPS (Basic, Before Extraordinaries)-2.08-2.29-1.46-151.220.00-0.01
EPS (Diluted)-2.08-2.29-1.46-151.220.00-0.01
EBITDA-135.93-122.66-61.97-25.89-1.83-0.23
Non-Operating Income (Expense)9.358.8610.300.991.86-0.23
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense18.849.654.212.73--
Shares Outstanding67.0152.0250.9823.2015.8115.81
Market Capitalization120.63120.63391.31343.05163.34163.34

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.180.180.190.170.130.110.100.08
Gross Profit-0.18-0.18-0.19-0.17-0.13-0.11-0.10-0.08
Selling, General and Administrative Excl. Other33.8431.7931.0039.3129.8227.0226.5117.37
Research and Development20.0922.2022.2531.7222.5720.2119.9711.27
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-34.01-31.97-31.18-39.48-29.95-27.12-26.61-17.45
Interest Expense0.840.740.730.750.760.730.750.76
Unusual Expense0.000.000.490.000.000.000.000.00
Net Income Before Taxes-32.50-30.23-29.75-38.38-28.75-25.57-24.60-15.28
Income Taxes0.000.000.00-0.500.240.240.020.02
Consolidated Net Income-32.50-30.23-29.75-37.88-28.99-25.82-24.62-15.30
Net Income From Continuing Operations-32.50-30.23-29.75-37.88-28.99-25.82-24.62-15.30
Net Income-32.50-30.23-29.75-37.88-28.99-25.82-24.62-15.30
EPS (Recurring)-0.47-0.43-0.44-0.74-0.57-0.51-0.48-0.34
EPS (Basic, Before Extraordinaries)-0.47-0.43-0.44-0.74-0.57-0.51-0.48-0.34
EPS (Diluted)-0.47-0.43-0.44-0.74-0.57-0.51-0.48-0.34
EBITDA-33.84-31.79-31.00-39.31-29.82-27.02-26.51-17.37
Non-Operating Income (Expense)2.362.492.651.851.952.282.772.93
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.814.142.804.082.042.091.431.31
Shares Outstanding67.0166.9966.9952.0251.1151.0750.9850.98
Market Capitalization120.63487.01638.36369.09193.69211.05341.54391.31

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments193.81238.4081.600.311.07
Short Term Receivables2.231.032.340.000.00
Inventories0.000.000.000.000.00
Other Current Assets5.357.931.500.200.50
Total Current Assets201.39247.3685.440.511.57
Net Property, Plant & Equipment10.192.910.590.000.00
Total Investments and Advances8.5259.530.07131.53129.67
Intangible Assets---0.000.00
Other Assets1.361.370.860.000.21
Total Assets221.47311.1786.96132.04131.45
Short Term Debt Incl. Current Port. of LT Debt10.021.120.560.000.00
Accounts Payable6.691.411.160.000.00
Income Tax Payable0.020.000.04--
Other Current Liabilities15.2612.133.500.890.33
Total Current Liabilities31.9814.665.260.890.33
Long Term Debt21.7823.909.220.000.00
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.000.000.003.733.73
Total Liabilities53.7638.5614.474.624.05
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity167.71272.6172.49127.42127.39
Total Shareholders Equity167.71272.6172.49127.42127.39
Accumulated Minority Interest0.000.000.000.000.00
Total Equity167.71272.6172.49127.42127.39
Total Liabilities & Stockholders Equity221.47311.1786.96132.04131.45
Book Value Per Share3.225.353.128.068.06
Tangible Book Value Per Share3.225.353.128.068.06
Full-Time Employees82573322
Price to Book Ratio0.521.706.941.291.29
Return on Assets-44.05-27.70-91.250.02-
Return on Equity-53.28-31.96-99.960.02-
Return on Invested Capital-61.90-18.60-122.290.02-0.18
Quick Ratio6.3016.8716.250.574.79
Current Ratio6.3016.8716.250.574.79

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-130.36-117.30-55.14-99.920.03-0.23
Depreciation0.720.510.320.17--
Other Funds (Non Cash)17.917.816.4475.52-1.860.00
Funds from Operations-111.73-108.98-48.38-24.23-1.83-0.23
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital8.429.740.10-0.521.08-0.57
Cash from Operating Activities-103.31-99.24-48.28-24.74-0.76-0.80
Capital Expenditures-0.69-1.49-0.93-0.320.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-31.35-23.65-125.030.000.00-129.66
Purchase of Investments-269.53-160.84-125.030.000.00-129.66
Sale Or Maturity of Investments238.18137.190.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-32.04-25.14-125.95-0.320.00-129.66
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock142.352.226.100.040.00131.53
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock142.352.226.100.040.00131.53
Proceedsfrom Stock Options116.800.000.000.000.00131.53
Issuance or Reduction of Debt, Net1.40-0.7012.4732.340.000.00
Change in Long Term Debt1.40-0.7012.4732.340.000.00
Issuance of Long Term Debt24.450.0021.9138.000.000.12
Reduction of Long Term Debt-23.05-0.70-9.45-5.660.00-0.12
Net Financing Active Other Cash Flow0.000.00247.1553.760.000.00
Other Financing Activities Uses0.000.00-13.00-10.500.000.00
Cash from Financing Activities143.751.52265.7286.150.00131.53
Exchange Rate Effect0.000.000.000.00--
Net Change in Cash8.40-122.8591.4861.09-0.761.07
Free Cash Flow-104.00-100.72-49.21-25.06-0.76-0.80
Preferred Dividends (Cash Flow)-0.000.00-0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments266.40258.54276.02193.81201.99217.46
Short Term Receivables2.882.921.202.230.710.53
Inventories0.000.000.000.000.000.00
Other Current Assets8.638.5412.005.358.629.98
Total Current Assets277.90270.00289.22201.39211.31227.97
Net Property, Plant & Equipment9.039.449.9110.199.853.19
Total Investments and Advances0.0026.7136.608.5223.0134.11
Other Assets1.391.381.391.361.381.38
Total Assets288.32307.52337.11221.47245.55266.65
Short Term Debt Incl. Current Port. of LT Debt2.452.482.5110.026.944.00
Accounts Payable2.541.792.446.692.381.57
Income Tax Payable0.000.000.000.020.570.33
Other Current Liabilities22.2217.2119.6715.2610.5512.11
Total Current Liabilities27.2121.4824.6131.9820.4418.00
Long Term Debt30.8230.8730.9621.7824.4421.36
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities58.0352.3655.5753.7644.8839.36
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity230.29255.17281.55167.71200.67227.29
Total Shareholders Equity230.29255.17281.55167.71200.67227.29
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity230.29255.17281.55167.71200.67227.29
Total Liabilities & Stockholders Equity288.32307.52337.11221.47245.55266.65
Book Value Per Share3.443.814.203.223.934.45
Tangible Book Value Per Share3.443.814.203.223.934.45
Full-Time Employees---82--
Price to Book Ratio0.521.732.961.840.850.84
Return on Assets-48.84-44.19-39.30-44.05-36.97-29.57
Return on Equity-60.50-52.58-46.07-53.28-43.95-33.97
Return on Invested Capital-12.45-10.57-9.52-19.99-12.88-10.38
Quick Ratio10.2112.5711.756.3010.3412.66
Current Ratio10.2112.5711.756.3010.3412.66

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-32.50-30.23-29.75-37.88-28.99-25.82
Depreciation0.180.180.190.170.130.11
Other Funds (Non Cash)7.944.153.202.622.161.61
Funds from Operations-24.38-25.90-26.36-35.09-26.70-24.10
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.43-4.60-2.5410.131.071.15
Cash from Operating Activities-18.95-30.50-28.90-24.96-25.63-22.95
Capital Expenditures0.00-0.10-0.15-0.44-0.70-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments30.1223.74-126.1440.942.0817.99
Purchase of Investments-42.38-50.21-169.19-7.75-44.67-13.76
Sale Or Maturity of Investments72.5073.9543.0448.6946.7631.75
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities30.1223.64-126.3040.501.3817.95
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.020.00140.331.990.030.20
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.020.00140.331.990.030.20
Proceedsfrom Stock Options0.000.00116.800.000.000.00
Issuance or Reduction of Debt, Net0.000.071.330.00-0.700.00
Change in Long Term Debt0.000.071.330.00-0.700.00
Issuance of Long Term Debt0.000.0724.390.000.000.00
Reduction of Long Term Debt0.000.00-23.050.00-0.700.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.020.07141.661.99-0.670.20
Exchange Rate Effect0.000.000.000.000.000.00
Net Change in Cash11.20-6.79-13.5417.53-24.92-4.80
Free Cash Flow-18.95-30.60-29.06-25.40-26.34-22.99

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.71%1.6M28.4M751.28K
2026-10-155.28%1.5M28.4M729.97K
2026-09-304.90%1.4M28.4M799.55K
2026-09-154.27%1.2M28.1M856.75K
2026-08-314.36%1.2M28.1M882.15K
2026-08-145.33%1.5M28.1M1.03M
2026-07-317.07%1.7M24.5M1.91M
2026-07-155.89%1.6M27.9M1.90M
2026-06-304.10%1.1M27.9M1.71M
2026-06-154.99%1.4M27.9M1.55M
2026-05-295.82%1.6M27.9M1.57M
2026-05-155.22%1.5M27.9M1.38M
2026-04-306.57%2.0M30.5M403.09K
2026-04-153.98%1.3M33.4M412.09K
2026-03-312.38%1.1M48.2M422.64K
2026-03-131.92%0.9M48.2M418.85K
2026-02-272.56%1.2M48.2M316.68K
2026-02-133.12%1.5M48.2M414.41K
2026-01-306.69%2.2M32.8M1.29M
2026-01-153.89%1.4M37.0M1.22M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.400.850.803.4613,6942250.913-0.0090.000
call2.000.000.200.152.62520618.000.458-0.0160.001
call3.000.004.400.004.3670.000.000.341-0.0250.001
put1.000.000.050.003.0512000.00-0.101-0.0070.000
put2.000.003.300.350.00010.000.00-0.532-0.0150.001
put3.000.004.300.000.0000.000.00-0.659-0.0250.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-07-31SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-22SCHEDULE 13GSEC
2026-07-223Initial statement of beneficial ownership of securities2026-07-16SEC
2026-07-223Initial statement of beneficial ownership of securities2026-07-16SEC
2026-07-178-KCurrent report2026-07-17SEC
2026-07-168-KCurrent report2026-07-15SEC
2026-06-188-K/A2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-04-30SEC
2026-06-158-KCurrent report2026-06-13SEC
2026-06-108-KCurrent report2026-06-09SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-13SCHEDULE 13GSEC
2026-05-08ARSAnnual report to security holders. 2025-10-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0910.05K100
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FCPM III SERVICES B.V.14.38%
BML Capital Management, LLC9.95%
Siren, L.L.C.9.34%
PERCEPTIVE ADVISORS LLC7.20%
AMERIPRISE FINANCIAL INC3.99%
Nextech Invest Ltd.3.47%
ADAR1 Capital Management, LLC3.14%
Vestal Point Capital, LP2.49%
ACORN CAPITAL ADVISORS, LLC1.90%
Peapod Lane Capital LLC1.55%

Funds

Fund% owned
Franklin Biotechnology Discovery Fund0.73%
Fidelity Nasdaq Composite Index Fund0.06%
Virtus Biotech Clinical Trials Etf0.05%
TIFF MULTI-ASSET FUND0.02%
JNL/DFA U.S. Small Cap Fund0.01%
NORTH SQUARE KENNEDY MICROCAP FUND0.01%
AST Small-Cap Equity Portfolio0.00%

OakChart. ENGN. Cached 15 minutes.